Pulmocide announces four presentations on PC945 at the 9th Advances Against Aspergillosis and Mucormycosis conference in Lugano, Switzerland, 27 February โ 1 March, 2020
London, UK, 2 March 2020 โ Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung […]